toward the costs of convening a workshop to examine the Food and Drug Administration’s use of the Emergency Use Authorization in order to ensure that it can become a more versatile public health and pandemic management vehicle
We use cookies to offer you a better browsing experience, analyze site traffic, personalize content, and serve targeted advertisements. Read about how we use cookies and our use of data by reading our new Privacy Policy. If you continue to use this site, you consent to our use of cookies.